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Abstract 
Background: Thermal injury during radiofrequency ablation (RFA) of atrial fibrillation (AF) can 
lead to pulmonary vein stenosis (PVS). It is currently unclear if routine screening for PVS by imaging 
(echocardiography, computed tomography) is clinically meaningful and if there is a correlation between 
PVS and the electroanatomical mapping system (EAMS) used for the ablation procedure. It was there-
fore investigated in the current single center experience. 
Methods: All patients from January 2004 to December 2016 with the diagnosis of PVS after interven-
tional ablation of AF by radiofrequency were retrospectively analyzed. From 2004 to 2007, transesopha-
geal echocardiography was routinely performed as screening for RFA-acquired PVS (group A). Since 
2008, diagnostics were only initiated in cases of clinical symptoms suggestive for PVS (group B).
Results: The overall PVS rate after interventional RFA for AF of the documented institution is 0.72% 
(70/9754). The incidence was not influenced by screening: group A had a 0.74% PVS rate and group B 
a 0.72% rate (NS). Referred to as the EAMS, there were significant differences: 20/4229 (0.5%) using 
CARTO®, 48/4510 (1.1%) using EnSite®, 1/853 (0.1%) using MediGuide®, and 1/162 (0.6%) using 
Rhythmia®. Since 2009, no significant difference between technologies was found.
Conclusions: The present analysis of 9754 procedures revealed 70 cases of PVS. The incidence of PVS 
is not related to screening but to the application of different EAMS. Possible explanations are technologi-
cal backgrounds (magnetic vs. electrical), learning curves, operator experience, and work-flow differ-
ences. Furthermore, incorporation of new technologies seems to be associated with higher incidences of 
PVS before workflows are optimized. (Cardiol J 2019; 26, 5: 451–458)
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Introduction
Thermal injury during radiofrequency abla-
tion (RFA) of atrial fibrillation (AF) can lead to 
pulmonary vein stenosis (PVS), a rare but com-
monly known adverse event [1–4]. Severe symp-
toms such as dyspnea and hemoptysis may occur. 
Catheter-based interventional treatment for PVS 
still remains a challenging field [3, 5–9]. To improve 
anatomical understanding and to reduce radiation 
exposure during ablation procedures, electroana-
tomical mapping systems (EAMS) were introduced 
[10]. Because the electroanatomical map is not able 
to portray the complex anatomy of the left atrium 
in its entirety, an image integration step of a pre-re-
corded heart extracted from computed tomography 
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(CT) or magnetic resonance imaging (MRI) was 
introduced [11]. The most widely used systems 
are CARTO® (Biosense Webster, Baldwin Park, 
CA, USA) and EnSite® (Abbott/St. Jude Medical, 
St. Paul, MN, USA). The main technological differ-
ence between these three-dimensional (3D) map-
ping systems is the electromagnetic localization 
of catheters in CARTO® and the impedance-based 
approach of the EnSite NavX/Velocity® technology. 
Since the introduction of EnSite Precision® in 2016 
providing magnetic catheter localization as well, no 
fundamental technological difference is present. It 
is unclear whether there is a relationship between 
the occurrence of PVS and the used EAMS during 
the ablation procedure for AF. Herein described, 
is a present single center experience. 
Methods
From January 2004 to December 2016 all 
patients with the diagnosis of PVS after interven-
tional ablation of AF by radiofrequency were col-
lected. Cases with catheter-based cryoablation or 
intraoperative RFA for AF were excluded. 
The study was approved by the local ethics 
committee and was done in accordance with the 
Declaration of Helsinki.
Definition of PVS
Minimal luminal diameter of stenosed pulmo-
nary veins (PVs) was measured on multi-planar 
reformatted 3D angiographic datasets (by contrast 
enhanced CT or MRI) of pre- and post-ablation 
imaging and PVS was expressed as percentage of 
post- vs. pre-ablation luminal diameter reduction. 
The degree of PVS is classified as severe with lu-
minal narrowing over 70%, moderate for 50–70% 
narrowing, and mild for < 50% narrowing [12].
Screening for PVS
From 2004 to 2007, transesophageal echo-
cardiography (TEE) was performed as routine 
screening for RFA-acquired PVS. The time of 
screening TEE was between 6 and 12 months after 
PV isolation or at the time of new symptoms sug-
gestive of  PVS. In cases of abnormal echo findings 
for PVs such as an accelerated peak flow over 1 m/s, 
a subsequent contrast enhanced CT or MRI timed 
for opacification of the PVs was performed to confirm 
and quantify the PVS. Also, in case of insufficient 
TEE quality, but typical symptoms suggestive for 
PVS, a subsequent imaging diagnostic was initiated.
Due to the low number of detected PVS and 
the logistic efforts required, routine screening was 
stopped. Since 2008, diagnostics were initiated only 
in cases of clinical symptoms suggestive for PVS. 
CT, MRI and/or PV angiography were the imaging 
methods used at this time. During this period, PVS 
of asymptomatic patients were detected as inciden-
tal findings in the context of re-ablation procedures. 
Ablation procedure
The present ablation approach has been previ-
ously described [13]. Briefly, interventional RFA 
for AF at the documented institution is performed 
under analgosedation. After the transseptal ap-
proach, the PVs are isolated point-by-point with 
an irrigated tip catheter using radiofrequency 
as the energy source. The ablation line is made 
antral circumferential around the left- and right-
sided PVs. Ablation inside the PVs was avoided. 
Additional ablation lines were performed at the 
discretion of the operator. Catheter navigation 
was supported by fluoroscopy and 3D EAMS. The 
choice of mapping tool and ablation catheter was at 
operator discretion. Intracardiac ultrasound guid-
ance was not used.
EAMS — CARTO®
At the documented institution, CARTO XP® 
was introduced in 1998. CARTO® works based on 
a magnetic field generated by a location pad placed 
under the patient’s chest [14]. Sensors embedded 
in the catheter tip enable catheter localization. 
A further sensor on the patient’s skin is used 
as a location reference. With further improve-
ment of the system (CARTO3®) by a combina-
tion of magnetic and current-based technology, 
visualization of multiple catheters has been avail-
able since 2009. In contrast to the EnSite NavX® 
system, the CARTO® allowed from the onset 
a reconstruction of the PVs as well as the whole 
atrium in one map (initially as point-by-point with 
CARTO XP® and later as fast anatomical map-
ping sampled by roving the catheter supported 
by CARTO3®). Since 2005, it is possible to merge 
the surfaces of a pre-recorded CT or MRI with the 
reconstructed map by the CARTOmerge® soft-
ware. Further registration steps are not necessary 
(Fig. 1: 1A–D).
EAMS — EnSite®
EnSite NavX® has been in use since 2005 in 
the present institution. The system works based 
on an electric field created by six skin electrodes 
in three orthogonal planes [15]. Catheter localiza-
tion is implemented by an impedance gradient in 
relation to a reference electrode. Later, for com-
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Figure 1. Workflow of the different electroanatomical mapping systems. Panel 1A–D. CARTO®, 1A. Segmented 
computed tomography (CT) shell of the left atrium; 1B. Reconstructed map by fast anatomical mapping; 1C. Fusion 
of the models by surface merging after setting a landmark at the posterior wall; 1D. Automatic visualization of abla-
tion points by the VISITAG tool without any additional steps of registration. Panel 2A-C. EnSite NavX® 2005–2008; 
2A. Segmented CT of the left atrium; 2B. Reconstruction of each pulmonary vein as separate geometry; 2C. Regis-
tration of the reconstructed three-dimensional shell in the electroanatomical mapping system. Panel 3A–D. EnSite 
Velocity® 2008–2016; 3A. Segmented magnetic resonance imaging (MRI) of the left atrium; 3B. Reconstruction of 
the left atrium and each pulmonary vein in one map; 3C. Fusion of 3A and 3B by fiducial points; 3D. Registered MRI 
shell with ablation points (red) projected on the 3D shell; Panel 4A–D. EnSite Velocity® supported by MediGuide®; 
4A, B. Snapshots of simultaneously displayed MediGuide® pre-recorded fluoroscopy loops in a right anterior oblique 
view (A) and left anterior oblique view (B) and corresponding location of the catheter ablation tip in the EnSite Velo-
city® supported map (C, D). The circular markers tag ostia of pulmonary veins after localization by contrast-enhanced 
angiography (A, B); Panel 5A–C. Rhythmia®; 5A. Segmented MRI of left atrium; 5B. Reconstruction of left atrium and 
each pulmonary vein; 5C. Fusion of map 5A and 5B. 
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pensation of cardiac and respiratory motion, an 
intracardiac reference catheter is usually placed 
into the coronary sinus. 
At the beginning of the EnSite NavX® sup-
ported RFA for AF, the workflow was to reconstruct 
the 4 PVs separately followed by a transmission 
into a pre-recorded CT or MRI model of the patient. 
A reconstruction of the atrium as well as PVs in 
one map was not possible (Fig. 1: 2A–C). Since the 
introduction of EnSite Velocity® as a next genera-
tion in 2008, the system allowed a reconstruction 
of the PVs as well as the whole atrium in one map 
followed by a merge with the CT or MRI. Thereaf-
ter registration steps of the merged map to confirm 
its accuracy were necessary (Fig. 1: 3A–D).
Since the introduction of EnSite Precision® in 
2016, which provides magnetic catheter informa-
tion as well, no fundamental technological differ-
ences are present between the systems at present.
MediGuide® technology
In 2011, the MediGuide® technology (Ab-
bott/St. Jude Medical, St. Paul, MN, USA) was 
introduced and became a standard in the present 
institution. By electromagnetic sensor-embedded 
catheter tracking in prerecorded fluoroscopy loops, 
the system allows additional X-ray imaging infor-
mation as well as integration of a PV angiography 
[16]. Working in combination with EnSite®, it 
represents a combination of magnetic and impe-
dance based tools that had been available for years 
before the introduction of EnSite Precision® in 2016 
(Fig. 1: 4A–D).
Rhythmia®
The recently developed EAMS Rhythmia 
Mapping® (Boston Scientific, Marlborough, Massa-
chusetts, USA) uses both magnetic and impedance 
information. The most important innovation of this 
system is an automatic record of high-resolution 
electroanatomical maps without manual annotation 
of the mapping points [17]. For RFA of AF, the 
workflow is to reconstruct the left atrium using 
a specially-designed mini basket (IntellaMap Orion®) 
followed by visual alignment with the pre-recorded 
CT/MRI shell (Fig. 1: 5A–C).
Statistical analysis
All analyses were performed using SPSS 
version 20.0 for Windows (SPSS Inc., Chicago, IL, 
USA). Continuous data with a normal distribution 
are reported as a mean and standard deviation. 
Discrete variables are reported as frequency 
(percentage). Groups were compared using the 
c2 test for categorical variables and ANOVA for con-
tinuous data. Bonferroni adjustment for multiple 
testing was done for post-hoc tests. All tests were 
performed two-tailed at significance level a = 1% 
(p < 0.01) due to the high number of patients. 
Results
Baseline characteristics
From January 2004 to December 2016, 9754 
patients underwent interventional RFA for AF in 
this institution. The most frequently used map-
ping systems were the CARTO® system with 
4229/9754 (43%) cases and the EnSite® system 
with 4510/9754 (46%). 853/9754 (9%) of the proce-
dures were supported by MediGuide® technology 
and 162/9754 (2%) by Rhythmia®. 
The patient cohort had a mean age of 66.6 ± 
± 10.3 years and were 65% male, presenting with 
paroxysmal AF in 62% of cases (Table 1). As for 
Table 1. Baseline characteristics.
Variable All  
(n = 9754)
CARTO®  
(n = 4229)
EnSite®  
(n = 4510)
MediGuide® 
(n = 853)
Rhythmia®  
(n = 162)
P
Age [years] 66.6 ± 10.3 67.1 ± 10.2 66.7 ± 10.2 63.4 ± 10.3 65.3 ± 10.3 < 0.001*
Male sex 6332 (65) 2751 (65) 2893 (64) 597 (70) 94 (58) 0.002+
Hypertension 6741 (69) 2850 (67) 3244 (72) 542 (64) 108 (66) < 0.001§
Diabetes mellitus 1575 (16) 645 (15) 801 (18) 107 (13) 24 (15) < 0.001§
CAD 1425 (15) 638 (15) 673 (15) 91 (11) 24 (15) 0.008*
Heart failure 2595 (27) 1100 (26) 1252 (28) 193 (23) 50 (31) 0.007+
Paroxysmal AF 5995 (62) 2734 (65) 2815 (62) 396 (46) 50 (31) < 0.001+
Non-paroxysmal AF 3759 (38) 1495 (35) 1699 (38) 457 (54) 113 (69) < 0.001+
Continuous data are represented as mean ± standard deviation and categorical data as number (percentage). P-values are given as overall 
value within the whole cohort; *Level of significance reached due to the MediGuide® group; +Level of significance reached due to the Medi-
Guide® and Rhythmia® group; §Level of significance reached between each group; AF — atrial fibrillation; CAD — coronary artery disease
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general cardiac risk factors, arterial hypertension 
was present in 69% of patients, diabetes mellitus 
in 16%, coronary artery disease in 15%, and heart 
failure in 27%. The distributions of these risk fac-
tors were statistically significant, with the difference 
being mainly driven by the MediGuide® group. 
These patients were healthier with regards to their 
cardiovascular risk factors but with a higher amount 
of persistent AF. In comparing the baseline charac-
teristic between CARTO® and EnSite®, the level of 
significance was only reached for arterial hyperten-
sion and diabetes mellitus (data not shown). 
Overall rate of PVS
Out of 9754 interventional RFA for AF, a total 
of 70 patients with PVS were identified. The overall 
PVS rate at the present institution is 0.72%. Dur-
ing the TEE screening period (group A), 9/1223 
(0.74%) patients with PVS were identified vs. 
61/8531 (0.72%, p = 0.972) without routine screen-
ing by TEE and CT/MRI (group B). 
Rate of PVS referred to mapping system
The rate of PVS revealed a significant dif-
ference referred to the applied mapping system: 
20/4229 (0.5%) for CARTO® vs. 48/4510 (1.1%) for 
EnSite® vs. 1/853 (0.1%) for MediGuide® and 1/162 
(0.6%) for Rhythmia® cases (p < 0.001) (Fig. 2). 
The significance level was due to the differ-
ence between the CARTO® vs. EnSite® cases as 
well as the EnSite® vs. the MediGuide® cases in 
the whole cohort (Fig. 2). 
The curve of incidence rates related to the 
year of RFA procedure showed for EnSite® mapping 
a peak around 2007 whereby in this year the num-
ber of EnSite® supported procedures was relatively 
small. In comparison, the CARTO® group showed 
a relatively stable percentage (Fig. 3). Since 2009, 
there was an alignment of the curves without 
a statistical difference in the PVS rate (Figs. 2, 3).
The mean degree of stenosis between the 
EnSite® and CARTO® group was 63 ± 28% nar-
rowing vs. 72 ± 24% (p = 0.184) and the amount of 
treated PVS with 31% vs. 30% (p = 1.0) was equal.
Discussion
The overall PVS rate for approximately 10,000 
RFA procedures of AF is 0.72% in the present 
institution. Since the change from ablation in or 
near the PVs to wide circumferential antral lesions, 
as well as the use of 3D mapping systems, the in-
cidence of PVS has decreased from initially 6.3% 
(estimated from publications between 1999 and 
2004) [18] to 1% [1, 4]. Compared to the reported 
data, the present single-center PVS rate reflects 
a comparable level.
Interestingly, routine screening using TEE 
and CT/MRI did not influence the percentage of 
identified PVS. Even though some asymptomatic 
PVS may have remained undiagnosed in group B, it 
was clinically reasonable to stop routine screening 
given the fact that no treatment would have been 
performed in these asymptomatic patients. 
Referring to the applied mapping system used 
during the RFA procedure, the lowest cumulative 
PVS rate was revealed for MediGuide® cases with 
0.1% and CARTO® cases with 0.5%. The overall 
PVS rate of EnSite® cases was significantly higher 
with 1.1%, although since 2009 an alignment of PVS 
rates was recorded. There are several different 
explanations for this result.
Technical background. Before introducing 
the new Precision platform in 2016, EnSite techno-
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Figure 2. Rates and significance levels of pulmonary vein stenoses referred to the used mapping system in total (A) 
and since 2009 (B); PVS — pulmonary vein stenosis. The level of significance was only reached in CARTO® vs. EnSite® 
and EnSite® vs. MediGuide® in total. Since 2009, no significant difference between technologies was found.
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logy was based exclusively on electrical infor-
mation for catheter localization. The potential 
limitation of this technology is its dependency 
on the body’s non-linear impedance distribution. 
Starting in 2008, the next generation system 
EnSite Velocity® was enabled to correct for this 
using a computer algorithm called “field scal-
ing”. Another frequent observation was map-
shifting after patient motion or dislocation of 
the reference electrode. In contrast, CARTO® 
technology was impedance-based as well as 
electromagnetic-based. In a phantom experi-
ment a significantly better point localization by 
CARTO3® in comparison to EnSite Velocity® 
could be demonstrated [19].
A randomized comparison of CARTOmerge® 
vs. EnSite NavX® in RFA for AF could demonstrate 
a significantly higher accuracy in lesion distance to 
the shell: 2.0 mm vs. 3.4 mm [20].
MediGuide® technology is a non-fluoroscopic 
catheter tracking system which works in combi-
nation with EnSite® [21]. Because of the fact that 
MediGuide® itself is electromagnetic based, the 
EnSite® system was functionally upgraded to 
a combined impedance and electromagnetic map-
ping tool. Its accuracy was shown to be superior 
to EnSite® only in a phantom [22].
Since the introduction of EnSite Precision® in 
2016, no fundamental technological differences be-
tween the competing systems are present to date.
Reconstruction and map fusion. Significant 
differences existed in the workflow with regards to 
EAM tools. The first version of EnSite NavX® was 
not able to reconstruct the whole atrium and PVs 
in one map. Furthermore, the lack of a field scaling 
algorithm often resulted in a flattened version of 
the left atrial anatomy. So it might be conceivable 
that inclusion of reconstructed PV’s with their 
orifices into pre-recorded CT was imprecise. Since 
2008 with the next version EnSite Velocity®, this 
problem was solved which might be a reason for the 
decrease in PVS rates since then. To integrate the 
reconstructed map into the pre-recorded CT/MRI 
shell, some fiducial points must be chosen in both. 
Due to the subjective election of its localization, it 
appears as a source of error.
On the other hand, reconstruction of the whole 
atrium and PVs in one map and a subsequent opera-
tor-independent surface merging with pre-recorded 
CT/MRI as the workflow of the CARTO® system 
right from the beginning could contribute to less reg-
istration errors and consequently lower PVS rates. 
Registration. After map fusion by several 
fiducials, the EnSite® system required a further 
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geal echocardiography.
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registration step to validate the map. It should 
be noted that a single incorrect registration point 
could produce a shifted map with unprecise lo-
calization of the PV ostia. There are data showing 
a higher precision of the surface-merge without 
a subsequent registration step for the CARTO® sys-
tem in comparison to the point-by-point technique 
of EnSite® [19]. The values ranged from 0.73 mm 
for CARTO3® vs. 2.02 mm for EnSite Velocity®.
In comparison, MediGuide technology unifies 
additional anatomical information of a PV angiogra-
phy whereas PV ostia are tagged by setting markers 
in pre-recorded cine loops. 
Operator experience. Knowledge of ana-
tomical orientation as well as know-how in the 
workflow of the different EAMS and their pitfalls 
might influence the rate of PVS substantially. 
With only a small number of Rhythmia® 
supported cases performed, a fundamental state-
ment seems to be unreasonable. Prior data did 
not show a difference in registration accuracy 
between pre-recorded CT or MRI for AF ablation 
procedures [23].
The influence of screening for the rate of PVS
In group A (year 2004–2007), over 1000 con-
secutively screened patients by TEE a PVS rate 
of 0.74% was evidenced. There was no significant 
difference in comparison to the period without 
screening in group B. TEE was shown to have 
a sensitivity of 84% and specificity of 98% in de-
tecting moderate PVS and appears to be a useful 
diagnostic tool [24, 25]. Nevertheless, measure-
ments of flow parameters and PV diameters are 
not accurate, especially of inferior PVs due to an 
unfavorable Doppler angle. Furthermore, detection 
of mild PVS remains a challenge [24].
However, there is no doubt that the rate of PVS 
is underestimated because of asymptomatic PVS 
and lack of routine screening. Obviously the PVS 
rate is influenced by factors such as energy titra-
tion, registration steps, and operator experience 
rather than on routine TEE screening. According 
to the current Consensus Statement on catheter 
and surgical ablation of AF from 2017, a routine 
screening for PVS after PV isolation is not recom-
mended [12].
The opinion herein, is that routine screening 
is not necessary because patients with severe PVS, 
but no symptoms, would not be treated particularly 
with regard to the risk-benefit balance. Despite 
a well-known increase of morbidity due to PVS, 
there is actually no data showing a higher mortality. 
Limitations of the study
The baseline characteristics between the 
groups of different EAMS are not balanced because 
of the retrospective nature of this registry analysis. 
However, there is no data showing an influence of 
cardiovascular comorbidities on the rate of PVS. 
There may be selection bias due to preference of 
the operators to different EAMS and varying leve-
ls of experience leading to an influence on PVS 
rates. Furthermore, when the MediGuide® was 
introduced, operators were already experienced 
with the EnSite® EAMS. Additionally, the study 
was performed in a single high-volume center with 
extensive experience in ablation of AF. As such, 
these data may not be easily applicable in cases 
of less experienced operators. Hence, analysis of 
experience from other centers would be desirable.
Conclusions
According to available research, this is the 
first analysis of the rate of PVS in a cohort of 
almost 10,000 patients. It was demonstrated that 
equal PVS rates, with and without screening, show 
significant differences between commonly used 
EAMS and the incidence of PVS after RFA for AF. 
Apart from technological differences between the 
EAMS, variances in workflow as well as operator 
experience might be influencing factors. Further-
more, the incorporation of new technologies seems 
to be associated with higher incidences of PVS 
before workflows are optimized.
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